“Screaming Value”: The Case For Circling Back To Bristol-Myers

2016-09-18 18_46_24-Morguefile free photographs for commercial use“To me, at these levels, it just screams value, even as you might have to wait a while for this investment to pay off.” This is Mad Money host Jim Cramer’s assessment of Bristol-Myers Squibb, shares of which plunged after “its flagship oncology drug, Opdivo, failed to meet its primary endpoint in a clinical trial”, resulting in analyst downgrades, estimate cuts and investors turning their backs on the company. So why does Cramer believe that investors should “circle back” to Bristol-Myers now? CLICK HERE to find out.